CDA Matched Antibody Pair (242) (APMAB-242LY)

Frances, A., & Cordelier, P. (2020). The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy?. Molecular Therapy, 28(2), 357-366.

Bjånes, T. K., Jordheim, L. P., Schjøtt, J., Kamceva, T., Cros-Perrial, E., Langer, A., ... & Riedel, B. (2020). Intracellular cytidine deaminase regulates gemcitabine metabolism in pancreatic cancer cell lines. Drug Metabolism and Disposition, 48(3), 153-158.

Murakami, Y., Kimura, Y., Kawahara, A., Mitsuyasu, S., Miyake, H., Tohyama, K., ... & Kuwano, M. (2019). The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. Oncotarget, 10(23), 2270.

Liu, W., Shang, F., Chen, Y., Lan, J., Wang, L., Chen, J., ... & Xu, Y. (2019). Biochemical and structural analysis of the Klebsiella pneumoniae cytidine deaminase CDA. Biochemical and biophysical research communications, 519(2), 280-286.

Moro-Bulnes, A., Castillo-Acosta, V. M., Valente, M., Carrero-Lérida, J., Pérez-Moreno, G., Ruiz-Pérez, L. M., & González-Pacanowska, D. (2019). Contribution of cytidine deaminase to thymidylate biosynthesis in trypanosoma brucei: intracellular localization and properties of the enzyme. Msphere, 4(4), e00374-19.

Peters, G. J., Giovannetti, E., Honeywell, R. J., & Ciccolini, J. (2019). Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. British journal of clinical pharmacology, 85(6), 1213.

Cohen, R., Preta, L. H., Joste, V., Curis, E., Huillard, O., Jouinot, A., ... & Blanchet, B. (2019). Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. British journal of clinical pharmacology, 85(6), 1227-1238.

Fanciullino, R., Farnault, L., Donnette, M., Imbs, D. C., Roche, C., Venton, G., ... & Costello, R. (2018). CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Advances, 2(5), 462-469.

Rajabpour, A., Afgar, A., Mahmoodzadeh, H., Radfar, J. E. D., Rajaei, F., & Teimoori-Toolabi, L. (2017). MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells. Cancer chemotherapy and pharmacology, 80(4), 765-775.

Corrie, P., Qian, W., Gopinathan, A., Williams, M., Brais, R., Valle, J. W., ... & Jodrell, D. (2017). Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). Annals of Oncology, 28, v251-v252.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-CDA Recombinant Antibody (921CT14.2.1)

Isotype control